Curated News
By: NewsRamp Editorial Staff
July 16, 2026

AI-Powered Blood Tests Revolutionize Heart Disease Detection

Discuss on Substack Discuss on Telegram View History of this news story on GitHub
Original Source

TLDR

  • Cardio Diagnostics' AI-driven tests detect heart disease missed by traditional methods, offering a competitive edge in the growing $1.4 trillion market.
  • The company's Multi-Omics Engine analyzes genetic and epigenetic biomarkers from a blood sample to assess coronary heart disease risk.
  • Early detection of heart disease through these tests can save lives and reduce healthcare costs, making tomorrow healthier.
  • Cardio Diagnostics uses AI to find nonobstructive coronary heart disease that conventional tests often miss.

Impact - Why it Matters

This news matters because cardiovascular disease remains the leading cause of death globally, yet many cases go undetected until it's too late. Cardio Diagnostics' AI-driven tests offer a noninvasive, blood-based method to identify heart disease and heart attack risk earlier, potentially saving lives and reducing healthcare costs. With reimbursement secured and international expansion underway, these tests could become widely accessible, empowering patients and doctors with precision diagnostics that outperform conventional tools.

Summary

Cardio Diagnostics Holdings (NASDAQ: CDIO) is revolutionizing cardiovascular disease detection with its AI-powered blood tests, Epi+Gen CHD and PrecisionCHD, which use artificial intelligence, epigenetics, and genetics to identify coronary heart disease and heart attack risk, including nonobstructive forms often missed by traditional methods. The company’s proprietary Multi-Omics Engine analyzes genetic and epigenetic biomarkers, positioning it in a cardiovascular disease market projected to swell from $393 billion in annual healthcare costs in 2020 to $1.4 trillion by 2050. Cardio Diagnostics has bolstered its commercialization by securing finalized CMS reimbursement rates and dedicated CPT laboratory codes, expanding U.S. provider partnerships, and launching its first international expansion in India. With a proprietary, AI-driven platform and growing evidence of its ability to detect what traditional tools miss, the company stands out as scientifically grounded and commercially actionable in the diagnostics landscape.

To view the full article, visit https://nnw.fm/9LJ2r. Cardio Diagnostics is an artificial intelligence-powered precision cardiovascular medicine company focused on making cardiovascular disease prevention, detection, and management more accessible and personalized. For more information, visit https://cdio.ai/. NetworkNewsWire (NNW), a specialized communications platform, distributed this news as part of its Dynamic Brand Portfolio @ IBN, which delivers wire solutions via InvestorWire, editorial syndication to 5,000+ outlets, enhanced press release distribution, and social media distribution to millions of followers. NNW is uniquely positioned to serve companies seeking broad investor and public recognition.

Source Statement

This curated news summary relied on content disributed by InvestorBrandNetwork (IBN). Read the original source here, AI-Powered Blood Tests Revolutionize Heart Disease Detection

blockchain registration record for this content.